In the combined radiotherapy cohort, in the group with low CK5 expression (less than its median) CK20 and MRE11 were associated with a lower risk of bladder cancer death (HR per unit increase 0.994, 95% CI: 0.990–0.998, p = 0.003, and 0.991 95% CI: 0.985–0.996, p = 0.0007, respectively). Here, KRT5 is linked to urinary bladder cancer.